<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119182</url>
  </required_header>
  <id_info>
    <org_study_id>1U01NS086090-01</org_study_id>
    <secondary_id>1U01NS086090-01</secondary_id>
    <nct_id>NCT02119182</nct_id>
  </id_info>
  <brief_title>Transforming Research and Clinical Knowledge in Traumatic Brain Injury</brief_title>
  <acronym>TRACK-TBI</acronym>
  <official_title>Transforming Research and Clinical Knowledge in Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of Transforming Research and Clinical Knowledge in Traumatic Brain Injury
      (TRACK-TBI) study is to determine the relationships among the clinical, neuroimaging,
      cognitive, genetic and proteomic biomarker characteristics for the entire spectrum of TBI
      from concussion to coma. TRACK-TBI will validate biomarkers and outcome measures for clinical
      trials, advance diagnostic and prognostic models for TBI and improve clinical trial design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective treatment of traumatic brain injury (TBI) remains one of the greatest unmet needs
      in public health. After 3 decades of failed clinical trials, a new approach is needed. Our
      proposal, Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI),
      establishes a public-private partnership of experienced TBI investigators, and philanthropic
      and industry collaborators, who share a mission to accelerate TBI research. TRACK-TBI will
      create a large, high quality database that integrates clinical, imaging, proteomic, genomic,
      and outcome biomarkers to establish more precise methods for TBI diagnosis and prognosis,
      refine outcome assessment, and compare the effectiveness and costs of TBI care.

      We hypothesize that this approach will permit investigators to better characterize and
      stratify patients, allow meaningful comparisons of treatments and outcomes, and improve the
      next generation of clinical trials. We have built on the TRACK-TBI Pilot study (NCT01565551)
      and our team's precompetitive collaboration, forged by participation in the TBI Common Data
      Elements project (TBI-CDE) and the International TBI Research Initiative (InTBIR). Having
      provided the index dataset for the Federal Interagency TBI Research database (FITBIR), we now
      propose the following Specific Aims:

      Specific Aim 1. To create a widely accessible, comprehensive TBI Information Commons that
      integrates clinical, imaging, proteomic, genomic, and outcome biomarkers from subjects across
      the age and injury spectra, and provides analytic tools and resources to support TBI
      research. Multi- disciplinary teams across 11 sites will enroll 3000 subjects of all ages
      across the injury spectrum of concussion to coma. Utilizing TBI-CDEs, along with uniform
      standards for acquiring multi-site MRI data, we will expand the TRACK-TBI Pilot informatics
      platform, leveraging existing informatics tools to populate FITBIR, yielding a resource for
      current and future TBI research and international collaboration.

      Specific Aim 2. To validate imaging, proteomic, and genetic biomarkers that will improve
      classification of TBI, permit appropriate selection and stratification of patients for
      clinical trials, and contribute to the development of a new taxonomy for TBI. We hypothesize
      that validated imaging, proteomic, and genetic biomarkers will permit improved patient
      classification, beyond traditional categories of mild, moderate and severe TBI.

      Subaim 2.1. To establish prognostic imaging biomarkers for TBI based on patho-anatomic
      analysis of CT and MRI, as well as quantitative MR volumetrics, diffusion tensor imaging
      (DTI), and resting state functional MRI (R-fMRI).

      Subaim 2.2. To identify blood-based biomarkers that will provide additional diagnostic and
      prognostic information with which to identify TBI phenotypes that can be targeted by specific
      therapies.

      Subaim 2.3. To identify common polymorphisms in candidate genes associated with outcome after
      TBI, and to elucidate causal molecular mechanisms of injury, response, and repair.

      Subaim 2.4. To construct a multidimensional TBI classification system incorporating data from
      multiple domains that will define homogeneous classes of patients suitable for clinical trial
      inclusion.

      Specific Aim 3. To evaluate a flexible outcome assessment battery comprised of a broad range
      of TBI common data elements that enables assessment of multiple outcome domains across all
      phases of recovery and at all levels of TBI severity. When compared with the current gold
      standard, the Glasgow Outcome Scale Extended (GOSE), we hypothesize that a flexible and more
      discriminating outcome battery reflecting multiple functional domains will more precisely and
      efficiently capture outcomes across the course of recovery, at all levels of TBI severity.

      Subaim 3.1. To improve the granularity and breadth of TBI outcomes using a flexible outcome
      assessment battery that enables basic neurocognitive assessment in subjects too impaired to
      undergo standard neuropsychological testing, and comprehensive assessment of cognition,
      functional status, mental health, social participation, and quality of life in those
      cognitively intact enough to provide valid results.

      Subaim 3.2. To determine the efficiency of a flexible outcome assessment battery, as compared
      with the GOSE, in reducing sample sizes needed to detect differences between groups.

      Subaim 3.3. To identify specific TBI phenotypes amenable to targeted interventions, by
      relating patient classification factors (Subaim 2.4) to different outcome factor scores
      (Subaim 3.1).

      Specific Aim 4. To determine which tests, treatments, and services are effective and
      appropriate for which TBI patients, and use this evidence to recommend practices that offer
      the best value. We will use established comparative effectiveness research (CER) and health
      economics methods to evaluate the ability of each clinical practice to improve outcomes while
      containing costs.

      Subaim 4.1. To identify patients currently admitted to an ICU who could be safely and
      effectively cared for in a floor bed or discharged home with outpatient management, and to
      estimate the health and economic impact of changing the management of these patients.

      Subaim 4.2. To determine whether routine follow up improves TBI outcomes and minimizes their
      economic burden.

      Subaim 4.3. To assess variability in management of patients taking antiplatelet agents at the
      time of TBI, and the effect of management on progression of intracranial hemorrhage, need for
      craniotomy, and outcome.

      We expect that achievement of these Specific Aims will advance our understanding of TBI,
      improve clinical trial design, lead to more effective patient-specific treatments, and
      improve outcome after TBI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow Outcome Scale - Extended (GOS-E)</measure>
    <time_frame>6 Months</time_frame>
    <description>The Glasgow Outcome Scale - Extended (GOS-E) is the current gold standard of outcome for TBI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3T Brain Structural and Functional Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Sagittal 3D T1 MPRAGE/IR-SPGR
Sagittal 3D T2* GRE
Axial Diffusion Tensor Imaging (DTI)
Axial Resting State Functional MRI (fMRI)
Sagittal 3D T2-FLAIR
Sagittal 3D T2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Specimen for Analysis of Biomarkers and Genetics</measure>
    <time_frame>Baseline Visit (In-Hospital)</time_frame>
    <description>7.0ml blood for plasma and DNA
7.0ml blood for serum
2.5ml blood for RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRACK-TBI Flexible Outcome Assessment Battery Framework (Composite Measure)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Abbreviated Battery
GOS-E
Confusion Assessment Protocol - Cognitive (CAP-COG)
Coma Recovery Scale Revised (CRS-R)
Comprehensive Assessment Battery
GOS-E
Expanded Disability Rating Scale (E-DRS-PI)
Rey Auditory Verbal Learning Test (RAVLT)
Trail Making Test (TMT)
Wechsler Adult Intelligence Scale IV (WAIS)
Brief Test of Adult Cognition by Telephone (BTACT)
Rivermead Post-Concussion Symptoms Questionnaire
Pain Intensity and Interference Instruments (PROMIS-PAIN)
Insomnia Severity Index (ISI)
Quality of Life After Brain Injury Overall Scale (QOLIBRI-OS)
Mayo-Portland Adaptability Inventory - Participation (MPAI-PART)
Satisfaction with Life Scale (SWLS)
12-Item Short Form Survey (SF-12)
Alcohol Use Disorders Identification Test 3-Item (AUDIT-C)
3-Item Drug Use Interview
Post-Traumatic Stress Disorder Checklist 5 (PCL-5)
Brief Symptom Inventory 18 (BSI18)
Participant Health Questionnaire 9 (PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRACK-TBI Flexible Outcome Assessment Battery Framework (Composite Measure)</measure>
    <time_frame>3 Months</time_frame>
    <description>Abbreviated Battery
GOS-E
Confusion Assessment Protocol - Cognitive (CAP-COG)
Coma Recovery Scale Revised (CRS-R)
Comprehensive Assessment Battery
GOS-E
Expanded Disability Rating Scale (E-DRS-PI)
Rey Auditory Verbal Learning Test (RAVLT)
Trail Making Test (TMT)
Wechsler Adult Intelligence Scale IV (WAIS)
Brief Test of Adult Cognition by Telephone (BTACT)
Rivermead Post-Concussion Symptoms Questionnaire
Pain Intensity and Interference Instruments (PROMIS-PAIN)
Insomnia Severity Index (ISI)
Quality of Life After Brain Injury Overall Scale (QOLIBRI-OS)
Mayo-Portland Adaptability Inventory - Participation (MPAI-PART)
Satisfaction with Life Scale (SWLS)
12-Item Short Form Survey (SF-12)
Alcohol Use Disorders Identification Test 3-Item (AUDIT-C)
3-Item Drug Use Interview
Post-Traumatic Stress Disorder Checklist 5 (PCL-5)
Brief Symptom Inventory 18 (BSI18)
Participant Health Questionnaire 9 (PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRACK-TBI Flexible Outcome Assessment Battery Framework (Composite Measure)</measure>
    <time_frame>12 Months</time_frame>
    <description>Abbreviated Battery
GOS-E
Confusion Assessment Protocol - Cognitive (CAP-COG)
Coma Recovery Scale Revised (CRS-R)
Comprehensive Assessment Battery
GOS-E
Expanded Disability Rating Scale (E-DRS-PI)
Rey Auditory Verbal Learning Test (RAVLT)
Trail Making Test (TMT)
Wechsler Adult Intelligence Scale IV (WAIS)
Brief Test of Adult Cognition by Telephone (BTACT)
Rivermead Post-Concussion Symptoms Questionnaire
Pain Intensity and Interference Instruments (PROMIS-PAIN)
Insomnia Severity Index (ISI)
Quality of Life After Brain Injury Overall Scale (QOLIBRI-OS)
Mayo-Portland Adaptability Inventory - Participation (MPAI-PART)
Satisfaction with Life Scale (SWLS)
12-Item Short Form Survey (SF-12)
Alcohol Use Disorders Identification Test 3-Item (AUDIT-C)
3-Item Drug Use Interview
Post-Traumatic Stress Disorder Checklist 5 (PCL-5)
Brief Symptom Inventory 18 (BSI18)
Participant Health Questionnaire 9 (PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3T Brain Structural and Functional Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>6 Months</time_frame>
    <description>Sagittal 3D T1 MPRAGE/IR-SPGR
Sagittal 3D T2* GRE
Axial Diffusion Tensor Imaging (DTI)
Axial Resting State Functional MRI (fMRI)
Sagittal 3D T2-FLAIR
Sagittal 3D T2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Specimen for Analysis of Biomarkers and Genetics</measure>
    <time_frame>2 Weeks</time_frame>
    <description>7.0ml blood for plasma and DNA
7.0ml blood for serum
2.5ml blood for RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Specimen for Analysis of Biomarkers and Genetics</measure>
    <time_frame>6 Months</time_frame>
    <description>7.0ml blood for plasma and DNA
7.0ml blood for serum
2.5ml blood for RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRACK-TBI Flexible Outcome Assessment Battery Framework (Composite Measure)</measure>
    <time_frame>6 Months</time_frame>
    <description>Abbreviated Battery
GOS-E
Confusion Assessment Protocol - Cognitive (CAP-COG)
Coma Recovery Scale Revised (CRS-R)
Comprehensive Assessment Battery
GOS-E
Expanded Disability Rating Scale (E-DRS-PI)
Rey Auditory Verbal Learning Test (RAVLT)
Trail Making Test (TMT)
Wechsler Adult Intelligence Scale IV (WAIS)
Brief Test of Adult Cognition by Telephone (BTACT)
Rivermead Post-Concussion Symptoms Questionnaire
Pain Intensity and Interference Instruments (PROMIS-PAIN)
Insomnia Severity Index (ISI)
Quality of Life After Brain Injury Overall Scale (QOLIBRI-OS)
Mayo-Portland Adaptability Inventory - Participation (MPAI-PART)
Satisfaction with Life Scale (SWLS)
12-Item Short Form Survey (SF-12)
Alcohol Use Disorders Identification Test 3-Item (AUDIT-C)
3-Item Drug Use Interview
Post-Traumatic Stress Disorder Checklist 5 (PCL-5)
Brief Symptom Inventory 18 (BSI18)
Participant Health Questionnaire 9 (PHQ-9)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Comprehensive Assessment with MRI</arm_group_label>
    <description>In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.
Phone Outcome Assessment at 3 months.
3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months.
Blood Draw for Plasma, DNA, Serum, RNA at baseline, 2 weeks, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comprehensive Assessment without MRI</arm_group_label>
    <description>In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.
Phone Outcome Assessment at 3 months.
Blood Draw for Plasma, DNA, Serum, RNA at baseline, 2 weeks, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brief Assessment</arm_group_label>
    <description>Telephone outcome assessment at 2 weeks, 3 months, 6 months, and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>In-Person Outcome Assessment</intervention_name>
    <description>NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.</description>
    <arm_group_label>Comprehensive Assessment with MRI</arm_group_label>
    <arm_group_label>Comprehensive Assessment without MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Phone Outcome Assessment</intervention_name>
    <description>NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.</description>
    <arm_group_label>Brief Assessment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3T Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>3T Research MRI at 2 weeks and 6 months.</description>
    <arm_group_label>Comprehensive Assessment with MRI</arm_group_label>
    <arm_group_label>Comprehensive Assessment without MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw for Plasma, DNA, Serum, RNA</intervention_name>
    <description>Blood draw at baseline, 2 weeks, and 6 months.</description>
    <arm_group_label>Comprehensive Assessment with MRI</arm_group_label>
    <arm_group_label>Comprehensive Assessment without MRI</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, Serum, DNA, and RNA will be collected at the time of injury. Plasma, Serum, and RNA
      will be collected at Day 3 and Day 5 if patient is in the hospital, and at 2 weeks and 6
      months post-injury. Samples will be banked at -80 degrees Celsius.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll adult patients of all ages presenting to the Emergency Department with a
        history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria,
        in which the patient has sustained a traumatically induced* physiological disruption of
        brain function, as manifested by â‰¥ one of the following:

        Any period of loss of consciousness Any loss of memory for events immediately before or
        after the accident Any alteration of mental state at the time of the accident (feeling
        dazed, disoriented, and/or confused) Focal neurologic deficits that may or may not be
        permanent

        *Traumatically induced includes the head being struck, the head striking an object, or the
        brain undergoing an acceleration/deceleration movement without direct external trauma to
        the head.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-100

          -  Documented/verified TBI by ACRM Criteria

          -  Injury occurred within 24 hours of ED arrival

          -  Acute brain CT as part of clinical care

          -  Visual acuity and hearing adequate for outcomes testing

          -  Fluency in English

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Significant polytrauma that woudl interfere with follow-up and outcome assessment

          -  Prisoners or patients in custody

          -  Pregnancy in female subjects

          -  Patients on psychiatric hold (e.g. 5150, 5250)

          -  Major debilitating baseline mental health disorders (e.g. schizophrenia or bipolar
             disorder) that would interfere with the validity of outcome assessment due to TBI

          -  Major debilitating neurological disease (e.g. stroke, CVA, dementia, tumor) impairing
             baseline awareness, cognition, or validity of outcome assessment due to TBI

          -  Significant history of pre-existing conditions that would interfere with likelihood of
             follow-up and validity of outcome assessment due to TBI (e.g. major substance abuse,
             alcoholism, end-stage cancers, learning disabilities, developmental disorders)

          -  Contraindications for MR (for CA+MRI cohort)

          -  Low likelihood of follow-up (e..g partipant or family indicating low interest,
             residence in another state or country, homelessness or lack of reliable contacts)

          -  Current participant in an interventional trial (e.g. drug, device, behavioral)

          -  Non-English speakers as most outcome measures are normed in the English language.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey T. Manley, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia S. Robertson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David O. Okonkwo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Diaz-Arrastia, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Uniformed Services University of the Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy R. Temkin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pratik Mukherjee, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph T. Giacino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Spaulding Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann-Christine Duhaime, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School, Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana P. Goldman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur W. Toga, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Smith, MSIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Opeolu M. Adeoye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neeraj Badjatia, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall M. Chesnut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gillian A. Hotz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher J. Madden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall E. Merchant, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex B. Valadka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seton Healthcare Family</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew I. Maas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antwerp University Hospital, Edegem, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David K. Menon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge, Cambridge, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Gagnon, PhD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Yue, BA, CCRC</last_name>
    <phone>415-206-4457</phone>
    <email>yuej@neurosurg.ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Vassar, RN, MS</last_name>
    <phone>415-206-8300</phone>
    <email>vassarm@neurosurg.ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John K. Yue, BA, CCRC</last_name>
      <phone>415-206-4457</phone>
      <email>yuej@neurosurg.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey T. Manley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pratik Mukherjee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther L. Yuh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vianca Caridad Cabera</last_name>
      <phone>305-585-6096</phone>
      <email>Vcc22@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gillian A. Hotz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Ross Bullock, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Spaulding Rehabilitation Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina R. Taylor, PhD</last_name>
      <phone>617-952-6392</phone>
      <email>srtaylor@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Yelena Guller, PhD</last_name>
      <phone>617-952-6308</phone>
      <email>yguller@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph T. Giacino, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Zafonte, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Fortes-Monteiro</last_name>
      <phone>617-724-2170</phone>
      <email>CFORTES-MONTEIRO@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ann-Christine Duhaime, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Rosand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Schmit, RN, BSN</last_name>
      <phone>513-558-6142</phone>
      <email>schmitpt@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Opeolu Adeoye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur M. Pancioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason T. McMullan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher J. Lindsell, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan J. Ratcliff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norberto Andaluz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jed A. Hartings, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Achala S. Vagal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Barcic, RN, BSN</last_name>
      <phone>412-648-9664</phone>
      <email>barcicp@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David O. Okonkwo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ava M. Puccio, RN, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Goeke</last_name>
      <phone>512-232-7830</phone>
      <email>esthergoeke@utexas.edu</email>
    </contact>
    <investigator>
      <last_name>David M. Schnyer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susie Madison, RN</last_name>
      <phone>214-648-2965</phone>
      <email>susie.madison@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher J. Madden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hunt H. Batjer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kim L. Rickert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen A. Figueroa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiana E. Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santhosh Sadasivan, MD</last_name>
      <phone>713-873-2789</phone>
      <email>sadasiva@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Claudia S. Robertson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harvey S. Levin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulina Sergot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TIRR Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Gonzalez, BA</last_name>
      <phone>713-797-7106</phone>
      <email>luis.gonzalez@memorialhermann.org</email>
    </contact>
    <investigator>
      <last_name>Mark Sherer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelle M. Sander, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall E. Merchant, PhD</last_name>
      <phone>804-338-0481</phone>
      <email>rmerchan@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Randall E. Merchant, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Wellnitz, RN</last_name>
      <phone>206-744-9319</phone>
      <email>wellnitz@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy R. Temkin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sureyya S. Dikmen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randall M. Chesnut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.commondataelements.ninds.nih.gov/tbi.aspx</url>
    <description>NINDS Common Data Elements</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Neuroimaging</keyword>
  <keyword>Psychological Health</keyword>
  <keyword>Comparative Effectiveness Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

